Antioxidants and methimazole in the treatment of Graves' disease: effect on urinary malondialdehyde levels.

Background: We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering this illness.

Methods: We evaluated the concentration of urinary and serum malondialdehyde (MDA) in 36 patients with Graves' disease.